Weekly Analysts’ Ratings Changes for SCYNEXIS (SCYX)

Several brokerages have updated their recommendations and price targets on shares of SCYNEXIS (NASDAQ: SCYX) in the last few weeks:

• 8/16/2026 – SCYNEXIS was upgraded by Wall Street Zen from “strong sell” to “hold”.
• 8/13/2026 – SCYNEXIS had its “buy” rating reaffirmed by Guggenheim. They now have a $33.00 price target on the stock, up from $24.00.
• 8/8/2026 – SCYNEXIS was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 7/31/2026 – SCYNEXIS had its “buy” rating reaffirmed by Brookline Capital Markets.
• 7/24/2026 – SCYNEXIS was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/10/2026 – SCYNEXIS was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/26/2026 – SCYNEXIS was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

SCYNEXIS, Inc is a late‐stage biopharmaceutical company focused on developing and commercializing novel anti‐infective therapies. Headquartered in Jersey City, New Jersey, the company’s primary research and development efforts center on combating invasive and chronic fungal infections, an area of high unmet medical need. SCYNEXIS’s scientific platform is built around its proprietary triterpenoid class of antifungals, which are designed to address resistance and safety limitations associated with existing treatments.

The company’s lead product candidate, ibrexafungerp, represents the first oral glucan synthase inhibitor to reach clinical development.